Last patient enrolls in phase 2 trial with Transgene’s TG4010 + nivolumab + chemotherapy for first-line treatment of advanced NSCLC

This article was originally published here

Transgene confirms that the study’s primary endpoint (objective response rate – ORR) on a minimum of 35 evaluable patients will be reported in Q4 2019. The Phase 2

The post Last patient enrolls in phase 2 trial with Transgene’s TG4010 + nivolumab + chemotherapy for first-line treatment of advanced NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply